Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Software equities regained footing on Tuesday after a string of partnership announcements tied to Anthropic's latest AI offerings suggested integration-focused adoption rather than outright displacement of existing software. Major software-related names and an ETF climbed as investors interpreted the news as a reduction in near-term disruption risk…
D.A. Davidson maintained a Buy rating on Primoris Services Corporation (PRIM) with a $150 price target even as the shares trade above that level. The call follows quarterly results that beat expectations, a book-to-bill ratio of 1.5x, modest year-over-year backlog growth and mixed profitability metrics that included higher costs on some renewables …
TD Cowen has reaffirmed its Buy rating on Avalo Therapeutics (NASDAQ: AVTX), pointing to meaningful upside tied to the company’s AVTX-009 program now in phase II development. The stock has climbed 83% over the past year and trades near $15.65, while analyst price targets published by various firms span $24 to $50. Market analysis tools also flag th…
DA Davidson has reaffirmed a Buy rating and a $95.00 price target on Boise Cascade Company (NYSE:BCC) after the company's reported fourth-quarter 2025 results. The firm highlighted stronger-than-expected distribution profitability and EBITDA hitting the high end of guidance, while management continued share repurchases and completed a strategic acq…
D.A. Davidson has reiterated a Buy rating and a $112 price target on UFP Industries (UFPI) following the company’s fourth-quarter 2025 report. The quarter missed consensus on both revenue and adjusted earnings, with margin pressure in Packaging and Construction cited as the primary cause. The analyst firm pointed to structural cost reductions, robu…
TD Cowen cut its price target on Hims and Hers to $17.00 from $20.00 while keeping a Hold rating, citing short-term uncertainty around regulatory implications for compounded injectable GLP-1s. The company reported fiscal fourth-quarter revenue and adjusted EBITDA that were up year-over-year but missed some analyst estimates. Multiple brokerages hav…
Shares of CPI Aerostructures (NYSE American: CVU) rose 5.8% on Tuesday after the company disclosed further orders from Lockheed Martin Aeronautics totaling $9 million. The work is tied to a previously announced Long Term Agreement and adds funding under an Indefinite Delivery, Indefinite Quantity contract, with shipments scheduled to continue throu…
Xcel Energy has agreed to provide power to Google’s forthcoming data center in Pine Island, Minnesota. The utility said the project will deliver 1,900 megawatts of new clean capacity to the grid - a mix of wind, solar and long-duration storage - with Google covering the project costs so existing customers are not charged.
DocuSign's stock climbed 5% following an announced collaboration with Anthropic to integrate intelligent contract workflows into the Cowork platform. The partnership follows Anthropic's expanded relationship with Salesforce in October 2025 to deploy Claude in regulated industries. Salesforce shares also rose 5%, even as premarket checks from BWG Gl…
21shares launched TSUI, a spot SUI ETF, on the Nasdaq on February 24, 2026, giving U.S. investors regulated, high-liquidity access to the Sui token through standard brokerage accounts. The ETF follows earlier U.S. offerings tied to SUI from 21shares and arrives amid growing institutional activity in the Sui ecosystem. Sui’s architecture, built on t…
Chinese drone manufacturer DJI has filed a legal challenge in the U.S. Court of Appeals for the 9th Circuit seeking to overturn an FCC decision that bars imports of its new drone models and critical components. The company says the rule harms its U.S. business and denies American customers access to its latest technology. The FCC's December action …
DA Davidson maintained a Buy rating and an $80.00 price target on Freshpet Inc. (FRPT), pointing to steady consumption patterns and the potential for growth if the company hits the midpoint of its fiscal 2026 outlook. Fourth-quarter 2025 results were broadly in line with estimates; revenue over the last 12 months reached $1.1 billion with roughly 1…
Wolfe Research has begun coverage of Neurocrine Biosciences with an Outperform rating and a $160 price objective. The firm projects Ingrezza to approach $3 billion in U.S. sales and sees Crenessity as a multi-hundred-million dollar opportunity in its first full year, while noting valuation metrics that suggest the stock may be trading below fair va…
Coinbase has expanded its platform to let all U.S. users trade stocks and ETFs alongside cryptocurrencies around the clock during market weeks. The offering includes zero-commission trades, instant funding with USD and USDC, fractional shares from $1, and a partnership with Yahoo Finance for one-click order execution. Coinbase says it will expand t…
Wolfe Research began coverage of uniQure BV (NASDAQ: QURE) with a Peerperform rating, noting clinical validation of AAV gene therapy and promising Phase 1/2 results for lead asset AMT-130 in Huntington's disease. The firm flagged the need for a defined regulatory pathway with the FDA and said it will remain on the sidelines until that clarity arriv…
Deutsche Bank downgraded Blue Owl Capital from Buy to Hold and reduced its price target to $10 from $15, citing expectations of weaker net inflows into retail private credit products. The bank made modest forecast reductions across its coverage of alternative asset managers and flagged the potential for elevated redemptions and softer new sales in …
Wolfe Research initiated coverage of Denali Therapeutics Inc. (DNLI) with a Peerperform rating, noting the company’s TransportVehicle platform and an advancing rare-disease franchise while flagging limited near-term market size for mucopolysaccharidoses. Analysts across Wall Street maintain price targets between $25 and $40 as the company approache…
Wolfe Research has begun coverage of Acadia Pharmaceuticals with an Outperform rating and a $33.00 price target, highlighting what it sees as a favourable pharmacokinetic profile versus an existing therapy. The stock, trading at $24.81, implies roughly 29% upside based on analyst consensus. Multiple brokerages have adjusted ratings and targets rece…
Wolfe Research opened coverage of Axsome Therapeutics with an Outperform rating and a $230 price target, citing strong commercial traction for Auvelity and a strategy to broaden the company's central nervous system product suite. Auvelity produced roughly $507 million in U.S. sales for major depressive disorder in 2025, helping drive a 66% surge in…
Advanced Micro Devices shares climbed about 5% after the company disclosed a supply arrangement with Meta Platforms to deliver AI computing infrastructure. Mizuho analyst Jordan Klein described the development as a clear positive for AMD, saying it should bolster confidence in upcoming products, while also flagging potential short-term trading head…
Federal Reserve Governor Lisa D. Cook said artificial intelligence offers substantial potential to raise productivity, but its rollout is already reshaping demand for certain jobs and could amplify labor market churn. Speaking at a major economic policy conference, she highlighted rising business investment in data centers and chips and cautioned t…
Wolfe Research has begun coverage of Centessa Pharmaceuticals (CNTA) with an outperform rating and a $40 price target, citing the company's ORX750 orexin-2 agonist as a potential best-in-class candidate and projecting more than $3 billion in peak U.S. sales. Centessa is approaching a Phase 2 data release for higher doses in the first quarter of 202…
RBC Capital has maintained an Outperform rating on Neurocrine Biosciences (NBIX) with a $177.00 price target, citing an apparent valuation gap relative to the company's commercial franchise. The firm points to near-term growth, a strong revenue base approaching $3 billion, and the potential to attract acquirers as key factors supporting upside. Rec…
Wolfe Research has begun coverage of Praxis Precision Medicines Inc. (NASDAQ: PRAX) with an outperform rating and a $500.00 price target. The firm highlights 2026 as a potentially transformative year for Praxis as the company advances programs in essential tremor and epilepsy, following two new drug applications filed in February. Despite a fourth-…
Wolfe Research launched coverage of Xenon Pharmaceuticals (XENE) with an Outperform rating and a $60.00 price target, citing the company’s lead Kv7 activator azetukalner. The firm projects multi-billion dollar peak sales across epilepsy and neuropsychiatric indications and points to an upcoming Phase 3 topline readout as a near-term milestone.
